Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Desmopressin Acetate

            Therapeutic Area: Urology Product Name: Nocdurna

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: ANTARES PHARMA INC

            Deal Size: $25.0 million Upfront Cash: $5.0 million

            Deal Type: Licensing Agreement October 01, 2020


            This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.